Am J Transplant, Volume 5, Suppl 3 Archives - Page 90 of 170 - ATC Abstracts

2015 American Transplant Congress
Microcirculation Inflammation in Early Surveillance Renal Biopsy in Sensitized Patients Did Not Correlate With Graft Outcome
P. Souza,¹ D. Machado,¹ D. David,¹ G. Bezerra,¹ F. Jota de Paula,¹ H. Rodriges,² W. Nahas,¹ E. David Neto,¹ M. Castro.¹
¹Renal Transplant Unit, HC - FMUSP, S Paulo, SP, Brazil; ²Lab de HLA, InCor, S Paulo, SP, Brazil.
Introduction: Microcirculation inflammation (MI) at 3-month renal biopsies and preformed donor-specific antibodies (DSA) are considered predictors of bad outcome in sensitized patients. Earlier biopsies and…
2015 American Transplant Congress
DQB1 Epitope Matching Predicts the Development of De Novo DSA and Antibody Mediated Rejection
M. Willicombe,¹ M. Blow,² P. Brookes,² E. Santos,² D. Taube.¹
¹Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, United Kingdom; ²H&I, Hammersmith Hospital, London, United Kingdom.
HLA DQ antibodies are the commonest de novo [DN] DSA specificity seen post renal transplantation. Their presence is associated with antibody mediated injury and allograft…
2015 American Transplant Congress
Eculizumab in the Treatment of Early Severe Acute Antibody Mediated Rejection Following HLA-Compatible Kidney Transplantation-Case Series
M. Singh,¹ N. Macias,² V. Tatapudi,¹ B. Lee.¹
¹Transplant Nephrology, UCSF Medical Center, San Francisco, CA; ²Nephrology, Hospital Gregorio Maranon, Madrid, Spain.
Severe early acute antibody-mediated rejection (AMR) is associated with poor allograft outcomes. Eculizumab is a humanized mouse monoclonal antibody against complement factor C5 that has…
2015 American Transplant Congress
Alemtuzumab Dose Adjusted for Weight Reduces Infection Post-Renal Transplantation
C.-H. Yoon, M. Willicombe, C. Jogia, R. Charif, J. Galliford, A. McLean, D. Taube.
Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Alemtuzumab [AL] has been increasingly used as an induction agent in renal transplantation. It causes potent lymphocyte depletion and as has been shown to reduce…
2015 American Transplant Congress
Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation
V. Whittaker,¹ D. Halleran,¹ S. Narsipar,¹ J. Melancon.²
¹Surgery, State University New York Upstate Medical University, Syracuse, NY; ²Surgery, George Washington University, Washington, DC.
Purpose: To report one year outcomes from single center experience with a novel induction regimen using anti-thymocyte globulin ( ATG)(rabbit)rATG (3 mg/kg) in divided doses…
2015 American Transplant Congress
Largest Single Center Experience of Pre-Transplant Outcomes After Bariatric Surgery in Ethnic Minorities With Chronic Kidney Disease
I. Thomas,² J. Gaynor,¹ T. Joseph,¹ N. De La Cruz,¹ D. Roth,² A. Mattiazzi,² W. Kupin,² L. Chen,¹ G. Burke,¹ M. Goldstein,¹ G. Ciancio,¹ G. Guerra.²
¹Surgery, University of Miami/Jackson Memorial Hospital, Miami, FL; ²Medicine, University of Miami/Jackson Memorial Hospital Miami Transplant Institute, Miami, FL, United Kingdom.
Background:Ethnic minorities have disproportionately lower renal transplant rates. The increased prevalence of obesity seen in ethnic minorities further places them at a disadvantage due to…
2015 American Transplant Congress
Sofosbuvir-Based Therapy for Hepatitis C Recurrence Post Liver Transplantation
A. Ajlan,¹ A. Aljedai,¹ H. Elsiesy,² D. Alkortas,¹ R. Alarieh,² F. Aba Alkhail.²
¹Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; ²Liver And Small Bowel Trans and Hep/Pancreatic Surgey -Organ Transplant Centre (OTC), King Faisal Specialist Hospital and Research Centre, Riaydh, Saudi Arabia.
Introduction:Sofosbuvir is approved to treat HCV infection in all genotypes with sustained virological response 12 weeks after completion of therapy (SVR12)rates of up to 100%.…
2015 American Transplant Congress
Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation
M. Gastaca,¹ I. Bilbao,² M. Jimenez,³ J. Bustamente,¹ C. Dopazo,² R. Gonzalez,³ R. Charco,² J. Santoyo,⁴ J. Ortiz de Urbina.¹
¹Liver Transplantation Unit, Cruces University Hospital. University of the Basque Country, Bilbao, Vizcaya, Spain; ²Hepatobiliopancreatic Surgery and Liver Transplant Unit, Hospital Universitario Vall d´Hebron, Barcelona, Spain; ³Unidad de Hepatología-Trasplante Hepático, Hospital Regional Universitario de Malaga, Malaga, Spain; ⁴Unidad de Cirugía Hepatobiliar-Trasplante Hepático, Hospital Regional Universitario de Malaga, Malaga, Spain.
Purpose: To study the safety and efficacy of immunosuppression with Everolimus (EVL) within the first month after orthotopic liver transplantation.Patients and methods: Recipients who had…
2015 American Transplant Congress
Day of Week Influences Kidney Utilization
K. Foley, M. Chiles, S. Mohan.
Department of Medicine, Columbia University Medical Center, New York, NY.
Background: From 2000 to 2013, 17% of all kidneys procured for transplantation from deceased organ donors in the United States were discarded. The high rate…
2015 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation
M. Uehara,¹ A. Jamil,¹ M. McGrath,¹ Z. Solhjou,¹ N. Banouni,¹ S. Tullius,² C. Jianjun,³ R. Abdi.¹
¹Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical Shcool, Boston, MA; ²Division of Transplant Surgery, Brigham and Women's Hospital, Boston, MA; ³Materials Science and Engineering, University of Illinois at Urbana-Champaign, Champaingn, IL.
Targeted nanodelivery has created enormous excitement as a transformative approach to deliver therapeutics to tissues of interest. In recent years, we have made significant progress…